Loading organizations...
Key people at Aliath Bioventures.
Aliath Bioventures was founded in 2023 by Montserrat Vendrell (Partner and co-Founder).
Aliath Bioventures is a venture capital firm and life sciences investment platform focused on biopharma, medical technology, and digital health startups, and is based in Barcelona and Madrid, Spain. Backed by AltamarCAM Partners, the firm managed €72 million in its first fund before launching a second vehicle with a €200 million target size. The organization directs capital into European healthcare ventures, building a portfolio that includes notable biotechnology companies such as Sanifit, Peptomyc, and SpliceBio. Following a recent integration into Asabys Partners, the combined entity manages over $468 million in assets under management across 25 holdings, with a strategic goal to reach a €1 billion platform by 2030. Originally established as Alta Life Sciences before rebranding in 2022, the firm was founded in 2017 by Guy Nohra, Montserrat Vendrell, Scott Moonly, and Miguel Valls.
Key people at Aliath Bioventures.
Aliath Bioventures was founded in 2023 by Montserrat Vendrell (Partner and co-Founder).
Aliath Bioventures is a Spain-based venture capital firm and healthcare sector impact investment platform within the AltamarCAM group, specializing in life sciences and healthcare investments.[1][2][5] Its mission is to generate competitive financial returns while addressing unmet medical needs and promoting healthcare system sustainability through innovative technologies in biotechnology/biopharma, digital health, medical devices, and diagnostics.[2][5] The firm follows an active investment philosophy, taking board positions in portfolio companies, with a primary focus on European opportunities weighted toward Spain and selective non-European deals; it manages impact-oriented funds like ABV II, AltamarCAM's first Article 9 vehicle under SFDR.[2] Aliath significantly bolsters the European life sciences startup ecosystem by bridging scientific expertise, institutional capital, and operational support, fostering disruptive solutions in high-growth areas like omics, AI-driven data analysis, and neuroprotective therapies.[2][5][6]
Aliath Bioventures emerged from the partnership between AltamarCAM and the Alta Life Sciences team, evolving from Alta Life Sciences SL, which advised AltamarCAM's Alta Life Sciences Spain I FCR fund.[2][5] Launched as an "Alliance for Impact on health," it reflects a strategic fusion to create dedicated life sciences venture capital impact funds under AltamarCAM's umbrella.[2][5] The platform is led by a seasoned team including Montserrat Vendrell, Scott Moonly, and José María Fernández, supported by scientific and VC advisors, with access to AltamarCAM's full platform for legal, ESG, finance, and investor relations.[2] In a recent development, Asabys Partners integrated Aliath Bioventures in late 2025, combining teams with prior co-investments in companies like Deepull, Ona Therapeutics, and Inbrain Neuroelectronics to form a leading European life sciences platform targeting over €1 billion AUM by 2030.[3]
Aliath Bioventures rides the wave of the "omics revolution," AI-enabled data analysis, and accelerating life sciences innovation, timing investments amid unprecedented healthcare discoveries to tackle sustainability challenges.[5] Favorable market forces include Europe's growing life sciences sector, gaps in tech transfer/scale-ups, and demand for impact investing under regulations like SFDR, positioning Aliath to fund disruptive therapies in CNS disorders, diagnostics, and digital health.[2][3][6] By advising AltamarCAM and partnering with Asabys, it influences the ecosystem through capital deployment (e.g., 18+ Asabys investments, 2 exits), board-level support, and collaborations that accelerate therapies like Accure Therapeutics' neuroprotective candidates.[3][6]
Aliath is poised to launch new funds post-Asabys integration, scaling toward €1 billion AUM by 2030 with a focus on high-impact life sciences segments from early-stage to growth.[3] Trends like AI in drug discovery, orphan disease therapies, and sustainable healthcare will propel its portfolio, amplified by its symbiotic model of investor-entrepreneur alliances.[2][5] Its influence will likely expand as a pan-European powerhouse, driving more exits and innovations that redefine accessible medicine—echoing its core mission to alliance-build for global health impact.[2][5]
